Literature DB >> 2535720

Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus.

R L Dewar1, V Natarajan, M B Vasudevachari, N P Salzman.   

Abstract

A recombinant adenovirus was constructed by inserting the human immunodeficiency virus type 1 (HIV-1) envelope gene downstream from the early region 3 (E3) promoter of adenovirus type 5 (Ad5), replacing the coding sequences of E3. The recombinant virus replicated as efficiently as the parent virus in all cell lines tested. Human cells infected with the recombinant virus synthesized the HIV-1 envelope precursor gp160, which was efficiently processed to the envelope glycoproteins gp120 and gp41. A human T-lymphoblast line (Molt-4) infected with the recombinant virus expressed HIV-1 envelope glycoproteins on the cell surface, leading to syncytium formation. The envelope gene was expressed from the E3 promoter at early times after infection and at late times from the major late promoter. When cotton rats were infected with the recombinant virus, antibodies against the HIV-1 envelope glycoproteins could be expressed in an immunoreactive form by the recombinant adenovirus, further illustrating the usefulness of adenoviruses as expression vectors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535720      PMCID: PMC247665     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.

Authors:  W G Robey; B Safai; S Oroszlan; L O Arthur; M A Gonda; R C Gallo; P J Fischinger
Journal:  Science       Date:  1985-05-03       Impact factor: 47.728

4.  HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients.

Authors:  R Crowl; K Ganguly; M Gordon; R Conroy; M Schaber; R Kramer; G Shaw; F Wong-Staal; E P Reddy
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Detection and characterization of the protein encoded by the v-rel oncogene.

Authors:  N R Rice; T D Copeland; S Simek; S Oroszlan; R V Gilden
Journal:  Virology       Date:  1986-03       Impact factor: 3.616

6.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

8.  Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome.

Authors:  I Saito; Y Oya; K Yamamoto; T Yuasa; H Shimojo
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

9.  Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.

Authors:  J S McDougal; A Mawle; S P Cort; J K Nicholson; G D Cross; J A Scheppler-Campbell; D Hicks; J Sligh
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  22 in total

1.  Expression of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant.

Authors:  M Gorziglia; A Z Kapikian
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.

Authors:  Shi-Hua Xiang; Andrés Finzi; Beatriz Pacheco; Kevin Alexander; Wen Yuan; Carlo Rizzuto; Chih-Chin Huang; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

4.  Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes.

Authors:  M R Castrucci; S Hou; P C Doherty; Y Kawaoka
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport.

Authors:  R L Dewar; M B Vasudevachari; V Natarajan; N P Salzman
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Studies on the stability of a human adenovirus-rabies recombinant vaccine.

Authors:  K K Kalicharran; V S Springthorpe; S A Sattar
Journal:  Can J Vet Res       Date:  1992-01       Impact factor: 1.310

Review 7.  HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

8.  Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.

Authors:  S M Cheng; S G Lee; M Ronchetti-Blume; K P Virk; S Mizutani; J W Eichberg; A Davis; P P Hung; V M Hirsch; R M Chanock
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Role of early region 3 (E3) in pathogenesis of adenovirus disease.

Authors:  H S Ginsberg; U Lundholm-Beauchamp; R L Horswood; B Pernis; W S Wold; R M Chanock; G A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  Packaging capacity and stability of human adenovirus type 5 vectors.

Authors:  A J Bett; L Prevec; F L Graham
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.